



Paratek Overview

*21st Annual H.C. Wainwright Global Investment Conference
New York, NY*

September, 2019

Recognizing the serious threat of bacterial infections, Paratek is dedicated to providing solutions that enable positive outcomes and lead to better patient stories.

Safe Harbor Statement

Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The information contained in this presentation is accurate only as of the date hereof. “Paratek” and the Paratek logo are trademarks and service marks of Paratek. All other trademarks, service marks, trade names, logos and brand names identified in this presentation are the property of their respective owners.

Certain statements in this presentation, including responses to questions, contain or may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include, but are not limited to, statements about our strategy, future operations, short and long term product revenue guidance, funding projections, prospects, including plans, objectives of management, availability of data from our clinical studies, potential use of our product candidates, including Omadacycline and Sarecycline, the market acceptance of our product candidates, the strength of, and protection offered by, our intellectual property position, the potential clinical risks and efficacy of, and market opportunities for, our product candidates, the timing and stability of our supply chain, the timing of clinical development of, and regulatory approval for, our product candidates, and the nature and timing of our collaboration agreements with respect to our product candidates. The words “anticipate,” “estimate,” “expect,” “potential,” “will,” “project” and similar terms and phrases are used to identify forward-looking statements. These statements are based on current information and belief and are not guarantees of future performance. Our ability to predict results, financial or otherwise, or the actual effect of future plans or strategies, is inherently uncertain and actual results may differ from those predicted depending on a variety of factors. Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations or whether the forward-looking statements ultimately prove to be correct. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include: delays in clinical trials or unexpected results; the risk that data to date and trends may not be predictive of future results; the failure of collaborators to perform obligations under our collaboration agreements; our failure to obtain regulatory approval for our product candidates; if we obtain regulatory approval for our product candidates, the risk that the terms of such approval may limit how we manufacture and market our product candidates; delays in our supply chain, delays in undertaking or completing clinical trials; our products not gaining the anticipated acceptance in the marketplace or acceptance being delayed; our products not receiving reimbursement from healthcare payors; the effects of competition; our inability to protect our intellectual property and proprietary technology through patents and other means; the need for substantial additional funding to complete the development and commercialization of our product candidates; and the other risks described in the “Risk Factors” section and elsewhere in our Annual Report on Form 10-Q for the quarter ending September 30, 2018, our Form 10-K for the year ended December 31, 2017, and our other filings with the SEC.

PARATEK® and the Hexagon Logo are registered trademarks of Paratek Pharmaceuticals, Inc. NUZYRA® and its design logo are trademarks of Paratek Pharmaceuticals, Inc.

Well-Positioned for Future Growth

Focused on Execution + New Value Creation

NUZYRA® 100mg for injection
& 150mg tablets



Near-term Execution

NUZYRA® U.S. Launch:
“Hospital-to-Home”

Disciplined Operating
Expense Management

Non-Dilutive Sources of
Capital



Future Value Creation

NUZYRA® Life-cycle
Opportunities

Bio-Defense

Product / Pipeline Expansion

Paratek Investment Highlights

NUZYRA®: Potential Blockbuster Antibiotic in Both Hospital and Community Settings

Potential Blockbuster Antibiotic with NUZYRA®

- 1st FDA approved and launched **once-daily oral & IV antibiotic** to treat both **CABP and ABSSSI** in nearly **20 years**
- **> \$9 Billion Potential** Addressable U.S. Market*

Clear Registration Path: U.S. FDA and EU EMA

- NUZYRA® U.S. FDA-**approved** in October 2018
- Filed in the EU in October 2018: **EMA Decision Projected 2H 2019**

Additional Pipeline Potential

- **UTI Ph2 Studies Underway**: Data Expected in Q4 2019
- **Biodefense opportunity**: Tx & Prophylaxis in Plague and Anthrax
- **Life-cycle opportunities**: Oral-Only CABP, Prostatitis, Rickettsial Disease

Capital Efficient Commercial Model

- **Significant Value Proposition** = Hospitalization Minimization
- **Hospital Promotion** with no other Branded Once-Daily Broad-spectrum Oral + IV Competitors

Non-dilutive Funding Options

- **Omadacycline**: Ex-U.S. Commercial Rights (Except Greater China)
- **Sarecycline**: Ex-U.S. Rights (PRTK)
- **BARDA / Bioshield**

(*) Paratek estimates based on 2015 AMR data current treatment failure rates and a Zyvox 2015 pricing analogue

Strong Track Record Delivering on Milestones


Omadacycline Events	Timing	Results
ABSSSI Phase 3 data: IV & oral	Q2 2016 ✓	Positive Phase 3 data
UTI Phase 1b data: PK/PD	Q4 2016 ✓	Proof-of-principle
CABP Phase 3 data: IV & oral	Q2 2017 ✓	Positive Phase 3 data
ABSSSI Phase 3 data: Oral-only	Q3 2017 ✓	Positive Phase 3 data
NDA approval	Oct 2018 ✓	Approved
U.S. Launch	Feb 2019 ✓	Launched
Response to Project BioShield RFP	June 2019 ✓	Submitted
UTI Phase 2 data: uUTI & Acute Pyelonephritis	Q4 2019	
Projected EMA Decision	H2 2019	
Oral-only Indication in CABP	H2 2020	

NUZYRA: A Modernized Tetracycline

Clinically Meaningful Attributes Drive Trial to Adoption



- Once-daily IV & Oral
- High & durable clinical efficacy in both CABP and ABSSSI
- No dosage modifications or monitoring in hepatic or renal impairment
- Low potential for DDIs
- No cardiac risk or QTc prolongation
- Low propensity for *C. diff*




- 📦 HCP confidence in treating patients
 - 📦 Efficacy
 - 📦 Safety
 - 📦 Tolerability
- 📦 Efficacy from **hospital to home**
 - 📦 Helps minimize hospitalization

NUZYRA U.S. Performance

U.S. Launch Underway

NUZYRA Net U.S. Revenues



- ❖ Launched in the U.S. in February 2019
- ❖ Accounting for inventory, NUZYRA gross revenue demand increased from approximately \$250 thousand in Q1 2019 to approximately \$1.7 million in Q2 2019
- ❖ Achieved institutional access in ~ 60% of the 400 plus targeted hospitals as of Q2 2019
- ❖ Through Q2 2019, over 50% of commercial lives in the U.S. now have access to NUZYRA and we have started to observe strong improvements with the government payers such that we have achieved close to 50% access in Medicaid
- ❖ Aided awareness within our target prescribers has increased from 27% at launch to greater than 50% in Q2 2019
- ❖ NUZYRA granted pass-through status and received a C-code for hospital out-patient setting (July 1, 2019) and J-code for all settings of care for the IV formulation (expected October 1, 2019)

NUZYRA®: Well Positioned for Blockbuster Potential

Antibiotic	Broad Spectrum	Big 3 ⁽¹⁾ Indications	Oral Frequency	2010 Sales ^(3,4)
Levofloxacin	✓	3	Once Daily	\$3.4B
Co-Amoxy clav	✓	3	Twice Daily	\$2.8B
Azithromycin ⁽²⁾	✓	2	Once Daily	\$1.8B
Ciprofloxacin	✓	3	Twice Daily	\$1.4B
Clarithromycin ⁽²⁾	✓	2	Twice Daily	\$1.4B
NUZYRA*	✓	2*	Once Daily	N/A

*Phase 2 studies in UTI currently underway; Topline data expected in Q4 2019

>65% of Revenue was Generated by the Oral Formulations

⁽¹⁾ Skin, Respiratory, UTI

⁽²⁾ Both Azithromycin and Clarithromycin did not have UTI claim

⁽³⁾ IMS global sales data in 2010

⁽⁴⁾ Major patents had expired for all products by 2010 except Levofloxacin where 2010 was peak year sales

Well-Positioned for Future Growth

Focused on Execution + New Value Creation

NUZYRA® 100mg for injection
& 150mg tablets



Near-term Execution

NUZYRA® U.S. Launch:
“Hospital-to-Home”

Disciplined Operating
Expense Management

Non-Dilutive Sources of
Capital



Future Value Creation

NUZYRA® Life-cycle
Opportunities

Bio-Defense

Product / Pipeline Expansion